Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: November 7, 2016
Reporting Period: Third quarter ended September 30, 2016
Context: This filing serves to announce the issuance of a press release detailing the company's financial results for the third quarter of 2016.
Key Financial Metrics
The provided text is a cover report (Form 8-K) and does not contain specific financial data points. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained in the attached press release (Exhibit 99.1), which is not included in the source text. Therefore, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes or comparative financial data are disclosed within the body of this Form 8-K. The document solely references the existence of the press release containing the results.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that management issued a press release on November 7, 2016, to report results, but the text of that commentary is not present in this document.
Legal Status of Exhibit: The press release (Exhibit 99.1) is furnished under Item 2.02 and is explicitly not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not subject to the liabilities of that section and shall not be deemed incorporated by reference in any other filings.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q3 2016 revenue, net income, and cash flow figures.
- Verify the company's cash position and liquidity status as detailed in the full press release.
- Check for any forward-looking statements or guidance provided in the press release text.
- Confirm the legal disclaimer regarding the non-filing status of the press release for liability purposes.